MRS study of the effects of minocycline on markers of neuronal and microglial integrity in ALS

Magnetic Resonance Imaging

Volumn 28, Issue 10, 2010, Pages 1456-1460

  Khiat, Abdesslem ^a   D'Amour, Monique ^a   Souchon, Frédérique ^a   Boulanger, Yvan ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Amyotrophic lateral sclerosis; Magnetic resonance spectroscopy; Metabolites; Minocycline

Indexed keywords

CHOLINE DERIVATIVE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; MINOCYCLINE; N ACETYLASPARTIC ACID;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MICROGLIA; MOTOR CORTEX; NERVE CELL; PRECENTRAL GYRUS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROGLIA; MIDDLE AGED; MINOCYCLINE; NEURONS; TISSUE DISTRIBUTION;

EID: 78449254316     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2010.06.032     Document Type: Article

References (26)

1. Blum D., Chtarto A., Tenenbaum L., Brotchi J., Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004, 17:359-366.
2. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002, 10:268-278.
3. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
4. Lampl Y., Boaz M., Gilad R., Lorberboym M., Dabby R., Rapoport A., et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007, 69:1404-1410.
5. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
6. Leigh P.N., Meininger V., Bensimon G., Cudkowicz M., Robberecht W. Minocycline for patients with ALS. Lancet Neurol 2008, 7:119-120. author reply 20-1.
7. Manev H., Manev R. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS. Amyotroph Lateral Scler 2009, 10:416-417.
8. Kalra S., Arnold D.L. ALS surrogate markers. MRS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004, 5(Suppl 1):111-114.
9. Kalra S., Hanstock C.C., Martin W.R., Allen P.S., Johnston W.S. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 2006, 63:1144-1148.
10. Wang S., Poptani H., Woo J.H., Desiderio L.M., Elman L.B., McCluskey L.F., et al. Amyotrophic lateral sclerosis: diffusion-tensor and chemical shift MR imaging at 3.0 T. Radiology 2006, 239:831-838.
11. 1H MRSI. Neurology 2002, 58:773-779.
12. Cwik V.A., Hanstock C.C., Allen P.S., Martin W.R. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998, 50:72-77.
13. 1H-Magnetic resonance spectroscopy in amyotrophic lateral sclerosis. J Neurol Sci 1999, 169:84-86.
14. Bowen B.C., Pattany P.M., Bradley W.G., Murdoch J.B., Rotta F., Younis A.A., et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000, 21:647-658.
15. Block W., Karitzky J., Traber F., Pohl C., Keller E., Mundegar R.R., et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998, 55:931-936.
16. 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001, 43:189-197.
17. Unrath A., Ludolph A.C., Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis: a longitudinal proton magnetic resonance spectroscopy study. J Neurol 2007, 254:1099-1106.
18. Kalra S., Tai P., Genge A., Arnold D.L. Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol 2006, 253:1060-1063.
19. Kalra S., Cashman N.R., Genge A., Arnold D.L. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998, 9:1757-1761.
20. Vielhaber S., Kaufmann J., Kanowski M., Sailer M., Feistner H., Tempelmann C., et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001, 172:377-382.
21. Kalra S., Cashman N.R., Caramanos Z., Genge A., Arnold D.L. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol 2003, 24:476-480.
22. Kalra S., Genge A., Arnold D.L.A. Prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:22-26.
23. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299.
24. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
25. Pohl C., Block W., Karitzky J., Traber F., Schmidt S., Grothe C., et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001, 58:729-735.
26. Ellis C.M., Simmons A., Andrews C., Dawson J.M., Williams S.C., Leigh P.N. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998, 51:1104-1109.